UNSPSC 51372309: Carbamethidine or oxpheneridine

This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OO7RKH9WL. European Medicines Agency schedules Oxpheneridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09553MIG. Oxpheneridine generally arises in the molecular formula C22H27NO3. The term OXPHENERIDINE is an International Non-Proprietary Name or INN. OXPHENERIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Carbamethidine or oxpheneridine bears US NLM identifiers UMLS ID C2698678 and NCI Concept Code C76844. SMILES: O(C(=O)C1(CCN(CC1)CC(O)C1CCCCC1)C1CCCCC1)CC.

UNSPSC 51372309 Carbamethidine or oxpheneridine is a Commodity code that in recent state and local procurement shows minimal direct relevance to the nominal chemical scope. The three recent opportunities posted under this code involve naloxone procurement (opioid overdose reversal), a therapeutic pharmacy initiative direct-to-manufacturer prescription program, and generic multi-source pharmaceuticals and OTC products — none of which align with carbamethidine or oxpheneridine chemistry or use cases. State and local agencies issuing under the code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance with Oregon participation). The mismatch between the code's nominal chemical scope and the actual procurement activity suggests either a cataloging error in state and local UNSPSC mapping or that the code is being used as a catch-all for pharmaceutical procurement that does not fit more specific codes.

Recent opportunities span Florida, Texas, and the Minnesota–Oregon cooperative region. Seminole County issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas HHS Commission posted an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products to be distributed through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026. Vendors responding to the MMCAP RFP must hold $5,000,000 commercial general liability insurance, comply with cGMP and Drug Supply Chain Security Act standards, maintain relationships with at least two authorized wholesalers, and accept a 3 percent administrative fee. Given the code's nominal scope does not align with recent solicitation activity, pursuit should focus on confirming whether your firm's pharmaceutical product actually falls under this code's intended taxonomy or whether opportunities of genuine relevance are posted under different UNSPSC codes.